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Objectives: The EPIPEN4SCHOOLS® program (Mylan Specialty L.P., Canonsburg, 
PA) provides epinephrine auto-injectors (EAIs) to qualifying schools in the United 
States. A pilot web-based survey of participating schools described anaphylactic 
events reported during the 2013-2014 school year.1This pilot survey was extended 
to large school districts (> 50 schools per district) to better understand prepared-
ness for anaphylaxis in such settings. MethOds: This cross-sectional, web-based 
pilot survey analyzed anaphylactic events in large districts participating in the 
EpiPen4Schools program. Results: Among 808 responding schools (representing 
47 districts), 286 anaphylactic events were reported. Of the 265 anaphylactic events 
with data on EAI use, 77.4% (n= 205) were treated by EAI. A stock EAI from the 
EpiPen4Schools program was used to treat 60.0% of individuals (96/160) experiencing 
an event. Of the 702 schools with information on staff training on anaphylaxis, 47.7% 
(335/702) provided training for the school nurse and select staff; 20.1% (141/702) 
and 29.2% (205/702) provided training for most staff and all staff, respectively. Most 
schools (62.3%, 437/702) permitted the school nurse and select staff to administer 
EAIs to treat anaphylaxis; 12.8% (90/702) and 18.9% (133/702) permitted most or all 
staff, respectively, to administer EAIs. cOnclusiOns: Sixty percent of individuals 
experiencing anaphylaxis were treated with EAIs from the EpiPen4Schools program, 
emphasizing the value of stocking EAIs. Notably, most schools permitted only the 
school nurse and select staff to treat anaphylactic reactions. Thus, students may 
routinely encounter staff members who cannot provide appropriate care during 
a life-threatening reaction. Because of the increased healthcare costs and risk of 
poor outcomes associated with delaying treatment of anaphylactic reactions with 
epinephrine, there is a continued public health need to remove barriers to EAI access 
and proper training in schools to recognize and manage anaphylaxis.
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Objectives: Similar to many European countries, performance-based financial 
incentives are introduced in the Netherlands to facilitate the implementation of 
integrated care programs. The aim of these programs is to enhance patients’ health 
by improving quality of care. Performance indicators are used to measure quality of 
care and reward healthcare providers. However, the real benefit to patients remains 
largely uncertain. This study investigate (I) if implementation of an integrated care 
program improves performance indicators and (II) the impact performance indica-
tors on health outcomes. MethOds: This is a sub-study of the RECODE cluster 
randomised controlled trial, the largest clinical trial of an integrated care program 
for Chronic Obstructive Pulmonary Disease (COPD) patients in primary care to date. 
From 38 Dutch GPs, we collected three-year prospective data on performance indica-
tors (mostly process indicators) and health outcomes (smoking status, level of physi-
cal activity, health-related quality-of-life (HRQoL)) of 913 COPD patients. Multilevel 
repeated measurement models were used to assess the impact of integrated care 
on performance indicators and the impact of performance indicators on health 
outcomes. Results: COPD performance indicators improved over time and these 
improvements were higher in the integrated care group than in the usual care group, 
indicating improved quality of care. Four indicators (whether BMI was measured, 
whether physical activity was checked, whether functional status was monitored, 
whether a spirometry test was done) were associated with an immediate improve-
ment (i.e. in the same year) in disease-specific HRQoL as measured with the SGRQ. 
The latter indicator plus ‘inhalation technique checked’ also had a delayed impact 
on HRQol (i.e. improved HRQoL in the year after the indicator was registered). The 
indicators related to smoking did not affect health outcomes. cOnclusiOns: The 
integrated care program did improve performance indicators of the quality of care 
and some of these indicators were predictive of improved HRQoL.
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Objectives: The expiration of patents for brand asthma medications and ongoing 
pressure on the healthcare budget resulted in a growing market for generic medica-
tions. Switching of inhaled drugs implicates change of inhalation device. Few data 
are available on the prevalence of switching from brand to generic asthma drugs. 
The objective of this study was to investigate the use of brand and generic asthma 
drugs and the prevalence of switching between brand and generic asthma drugs 
in patients with asthma in the Netherlands MethOds: From the Dutch PHARMO 
Database Network, all dispensed asthma drugs with generic availability in 2003-2012 
of asthma patients aged > 5 years were extracted. The prevalence of dispensing was 
calculated as percentage of users per calendar year per asthma drug and all asthma 
drugs combined. Switching was defined as mixed use: generic after brand dispensing 
or vice versa. Results: The cohort included 31,295 pediatric and 54,324 adult users 
with in total 380,510 dispenses over 2003-2012. All drugs combined, the proportion 
of children using only brand drugs decreased from 73% in 2003 to 54% in 2012, while 
only generics increased from 8% to 17% and mixed (both brand+generic) from 19% 
to 29%. Similarly, the proportion of adults with only brand dispenses decreased from 
and then translated into Urdu by using standard translating procedure which 
consist of 18 questions to evaluate the knowledge and awareness.Convenient 
sampling technique was used and around 330 questionnairewere distributed 
among teachers. Descriptive analysis to demonstrate patients’ demographics. 
Knowledge score is calculated as 18 as there are 18 questions with one score for 
each right answer and total score is divided in two grades with low grade of knowl-
edge (0-9 score) and high grade score (10-18 score). Inferential statistics (Mann-
Whitney and Kruskal Wallis test, p< 0.05) were used to differentiate or relate the 
study variables. Results: A total of 330 questionnaire were distributed with the 
response rate of 90%. One hundred ninety nine (64.4%) were from Private schools. 
Majority of respondents 114 (38.4%) belong to age 25-31 years.One hundred and 
ninety (64.0%) teachers were female. The graduates were 58 (19.5%). Majority of 
respondents 191 (64.6%) have experience of 1-5 years in teaching. One hundred 
and seventy two (57.7%) having good knowledge regarding asthma. It is also noted 
that knowledge of female teachers is good as compared to male teachers. Gender 
dominantly affect (P < 0.05) the knowledge of the respondents. cOnclusiOns: 
This study highlights that although majority of school teachers having poor knowl-
edge regarding asthma. It is advised to train and educate the school teachers to 
recognize the early symptoms of asthma.
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Objectives: The tobacco industry is actively developing modified risk tobacco prod-
ucts (MRTPs) with the potential to reduce tobacco-related mortality and morbidity 
in the population. The 2012 FDA Draft Guidance on MRTP applications asks appli-
cants to conduct consumer-based research on the perceptions of risk associated 
to tobacco products. This study reports on how qualitative methods described in 
the 2009 FDA Guidance on Patient-Reported Outcome Measures can be used with 
cognitive debriefing interviews (CDI) to understand how consumers interpret the 
complexities of risk ratings. MethOds: Reanalysis of CDI transcripts on a new risk 
perception measure, the Perceived Risk Instrument (PRI), was used to explore ways 
that consumers evaluate tobacco product health risk. 48 interviews were conducted 
in two US cities over four days. 24 individuals completed the PRI as applied to con-
ventional cigarettes (CC) and 24 as applied to MRTPs. Codification and thematic 
frequency analysis followed commonly accepted standards. Results: Thematic 
saturation occurred on the first day and by the end of the second day all content 
themes were defined. Daily refinements of the PRI lead to a reduction of the number 
of concerns expressed over time. The frequency of some risk evaluations for CC and 
MRTP were similar: For example the general degree of difficulty rating risks (CC, 
58% vs. MRTP, 46%); and the need for clear time frames to evaluate risk (CC, 21% vs. 
MRTP, 29%); while other evaluations differed by product, such as unfamiliarity with 
product risks (CC, 0% vs. MRTP, 25%). cOnclusiOns: Qualitative methods can be 
used with CDI data to refine risk perception measures. Understanding the ways 
consumers evaluate the risk associated with tobacco product use is necessary to 
create instruments that provide accurate data to inform public health policies. Such 
considerations also help improve population-based research and evidence-based 
product assessment.
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Objectives: To present recent experiences about the Italian model for granting 
initial reimbursability of innovative therapies. This model is based on a Register 
whose aim is to warrant appropriate prescribing, and on a conditional agree-
ments (risk-sharing) until drug effectiveness/tolerability is confirmed in clinical 
practice. MethOds: As an example of implementation of the Italian method, we 
report the re-negotiation process of pirfenidone in the treatment of idiopathic pul-
monary fibrosis. The first reimbursement authorization (2013) was granted along 
with a risk-sharing agreement (Success Fee) and pirfenidone inclusion in the AIFA 
Register. The aim of these tools was to assure from the initial access a proper cost-
benefit profile also when evidence from clinical practice was limited. Results: 
The Register warranted pirfenidone appropriate utilization according to clinical 
trials eligibility criteria. This made it possible to achieve adherence and persis-
tence rates with therapy greater than EU values (80%ITA vs. 72%EU and 73%ITA vs. 
50%EU, respectively).1 When the agreement had to be renegotiated, new clinical 
data from Phase III randomized trials2 and clinical practice3, supporting pirfeni-
done value, were submitted in order to reassess the cost-benefit profile. Due to 
this evidence, AIFA overcame the initial uncertainty about the benefit in clinical 
practice and agreed to remove the risk-sharing mechanism; the drug, however, is 
still present in the Register in order to evaluate appropriateness of prescribing pat-
terns. cOnclusiOns: This approach, based on an initial risk-sharing agreement, 
to minimize effectiveness uncertainties, allows post-marketing reassessment of 
health technologies, consistent with current health policies. It is expected that 
in the future there will be an increased utilization of data collected through AIFA 
Registers for reassessment of innovative therapies.  
ReFeRences: 
1. Roche,data on file.
2. King TE Jr,Bradford WZ,Castro-Bernardini S,et al.(ASCENDStudyGroup). NEngl J 
Med.2014;370(22):2083-92.
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cost 0.2 % to 58.01 % of the average monthly salary of the patient. In 2014, the least 
affordable drugs for patients with COPD were drugs from the inhaled corticosteroids 
group: Flixotide nebules, Nebufluzone and Pulmicort, the cost of which varied from 
19.86% to 58.01%, which can be afforded only by patients with incomes above the 
average. The most affordable drug is a short-acting β 2-agonist– salbutamol (Ca.s. 0.43-
15.70%). cOnclusiOns: Ukraine faces a rather difficult situation for patients with 
COPD. Drugs recommended by GOLD are presented insufficiently, and a large number 
of drugs available in the market are not readily available to patients.
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Objectives: Asthma is a chronic inflammatory airway disease that causes a 
significant economic and humanistic burden. The objective of this study was to 
systematically review the evidence on cost and resource utilization in uncontrolled 
and persistent asthmatic patients in Canada. MethOds: A literature search was 
performed using keywords such as “asthma”, “hospitalization”, “medical services”, 
and “cost”. The search was conducted in the MEDLINE, EMBASE and PubMed elec-
tronic databases from January 1st 2005 to May 28th, 2015. To be eligible, studies had 
to be Canadian, focus on uncontrolled or persistent asthma and include cost or 
resource utilization data. Results: The search retrieved 17,335 studies of which 
7 fulfilled the eligibility criteria. Among the 7 retrieved studies on uncontrolled or 
persistent asthma, 6 reported resource utilization data and 3 reported cost data. 
Among the resource utilization studies, 6 reported data on hospitalizations, 4 on 
emergency department (ED) visits and 3 on physician visits at a patient-level. The 
hospitalization rate ranged from 15% to 64.5% per patient per year and the mean 
hospitalization length of stay was 1.83 days. The rates for ED visits ranged from 
3.4% to 50.4% with 2 studies reporting rates over 20%. One study reported a mean 
physician-visit rate of 50% per patient per year while another study reported that 
64.3% of the patients had at least 4 physician-visits per year. In the cost studies, 
the total mean direct cost in adjusted 2015CDN$ per patient per year ranged 
from $413 to $1,764, carrying overall additional cost for uncontrolled asthma to 
nearly $189 million annually in Canada. cOnclusiOns: This analysis indicates 
that uncontrolled and persistent asthma is associated with considerable cost and 
resource use, especially regarding hospitalizations, ED visits and physician visits 
at a patient-level, thus leading to an important economic burden at a population-
level in Canada.
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Objectives: Greece has increasing prevalence of tobacco use and one of the 
highest consumption rates in Europe. Notwithstanding that tobacco tax is an 
important fiscal revenue, smoking represents a major public health threat causing 
premature mortality, morbidity, costs and foregone productivity which are a major 
source of fiscal loss. The objective of this study was to assess the net fiscal impact 
of hypothetic tax increases to inform public policy. MethOds: Evidence for the 
prevalence of smoking and smoking-attributable mortality (SAM) in Greece was 
synthesized with economic data to assess the net fiscal impact of tobacco use. 
SAM was converted into productivity (earnings) loss and tax revenue (fiscal) loss. 
Mincer functions were used to project lifetime earnings and direct and indirect per 
person tax for smokers and ex-smokers. Average tobacco consumption was used to 
quantify the expected tax revenue from tobacco consumption tax and published 
price elasticities were employed to explore the impact of hypothetical tax and 
price increases. Results: The averted mortality, by a 10% increase in the price of 
tobacco products, is expected to avert productivity loss of € 4.4-6.9 million that cor-
responds to averted fiscal loss of € 1.5-2.5 million as measured by expected lifetime 
tax. Based on previous studies, healthcare cost savings were estimated by previous 
studies at € 24-€ 149 million. Higher price increases yielded higher epidemiological, 
societal and fiscal benefits. Tobacco consumption appears to be inelastic thus, tax 
revenue was not reduced in the absence of lower consumption. cOnclusiOns: 
Smoking represents both a source of fiscal revenue and loss for central govern-
ment. Price increases, through tobacco tax, may be a fiscally meaningful pol-
icy for reducing the burden of smoking. Although there are likely to be upper 
limits to which further tax increases will not discourage tobacco consumption. 
Assessing the net fiscal impact may be a useful tool for tobacco-control policy 
evaluation.
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Objectives: Exacerbations of COPD contribute to overall disease severity and can 
be an important driver of increased healthcare resource utilisation. This study 
aimed to estimate COPD exacerbation rates and assess primary and secondary care 
resource utilisation in England, using GOLD 2013 categories from A: low risk, less 
symptoms to D: high risk, more symptoms. MethOds: Patients with a diagnosis 
of COPD aged ≥ 40 years before January 1, 2011, registered in the Clinical Practice 
Research Datalink linked to Hospital Episode Statistics with complete spirometric 
and modified Medical Research Council Dyspnoea Scale information and exacer-
bation history were included and further classified into GOLD risk groups. Patient 
characteristics were described at baseline. Study outcomes were exacerbations 
rates, and resource utilisation comprised of general practitioner (GP) visits and 
77% in 2003 to 72% in 2012, only generic increased from 7% to 9% and mixed from 
16% to 19%. In 2012 the proportion generic dispenses was highest for salbutamol with 
53% in children and 51% in adults. cOnclusiOns: Generic dispensing is increasing, 
probably due to preferential policy of the Dutch healthcare insurances. Switching 
drugs may increase confusion and mistakes in inhalation technique, causing less 
effective treatment and lower adherence.
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Objectives: COPD market is highly boosted by combinations caused by over-
treatment and misclassification of the patients. Physicians have high tendency 
to prescribe triple combinations for COPD patients without making classification 
for severity. The objective of this analysis is to develop a clinical guideline based 
budget impact model for COPD to inform reimbursement decision. MethOds: 
A model was developed to estimate the four-year budget impact of gradually 
increasing compliance with clinical guideline based treatment in COPD patients 
who are currently under overtreatment. Only inhaler drug acquisition costs from 
payer perspective were considered for each treatment class defined in the guide-
line. Inputs for the model were derived from 2 studies to compare the inhaler 
consumption in practice and guideline recommendation by categories. Patient per-
centage and treatment class used in each category are obtained from ALPHABET 
study, projected to the currently treated COPD population in Turkey. Indacaterol, 
a LABA, was taken into account as a first step of complying with guideline-based 
treatment approach based on its superior outcomes in first line medication. The 
model did not account for patient co-payments, drug prices are assumed to be 
constant in 4 years. Results: For a COPD market with a treatment regimen 
gradually complying with GOLD guideline in 4 years, the model estimated 20%( 
mioTL -24.7) cost reduction in government budget. From first to fourth year, the 
impact is -13%(mioTL-5.8),-17%(mioTL-6.0),-22%(mioTL-6.3) and -26%(mioTL-6.6) 
respectively. cOnclusiOns: The model budget impact of implementing clinical 
guidelines with evolving treatment regimen towards LABA and LAMA combina-
tions and its mono components may reduce the overuse of drugs and government 
spending on COPD treatments. Based on these assumptions, budget impact of 
future treatment that will help physicians to comply with treatment guidelines 
may change. Model can be adapted accordingly. Reimbursement bodies might be 
better off moving toward aligning reimbursement decisions with clinical guide-
lines in the future.
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Objectives: 1) To study the clinical, radiological and epidemiological features of severe 
pneumonia in children in age group of 1 month to 5 years of age; 2) To correlate clinical 
findings with radiological and bacteriological examination; 3) To know the choice of 
antibiotic for severe pneumonia. MethOds: This was a prospective clinical study of 
severe pneumonia conducted on 200 children who were admitted to pediatric wards 
from October 2010 to September 2012 at Gout General Hospital, Guntur. The epidemio-
logical factors affecting the same were also studied. Results: Age groups/Number of 
cases Percentage: 1m–6m/67 33.5; 7m–12m/52 26; 13m–60m/81 40.5. Table 1: Distribution 
of cases according to age Sex Number of cases Percentage Male 130 65 Females 70 35 
Table 2: Distribution of cases according to sex Symptoms Number Percentage Cough 
199 99. 5 Fever 184 92 Hurried breathing 200 100 Refusal of feeds 80 40 Wheeze 50 25 
Convulsions 15 7. 5 Cyanosis 8 4 Table 3: Showing various symptoms cOnclusiOns: 
ARI, especially severe pneumonia is one of the major causes of morbidity and mortality 
in children. Bronchopneumonia is the predominant form of presentation in infants and 
preschool children. Among the risk factors studied, inappropriate immunization for 
age, anemia, PEM grade III and IV were significant risk factors in severe pneumonia. 
Symptoms and signs mentioned in the WHO ARI control programme were very sensi-
tive and can be applied to hospitalized children. Chest X-ray is a valuable aid in the 
diagnosis of pneumonia in children. Follow up chest roentgenogram is vital for evaluat-
ing the response to treatment in pneumonia. Crystalline Penicillin and amikacin are 
still the antibiotics of choice in pneumonia. Indiscriminate use of higher antibiotics in 
not justified, in view of emergence of drug resistant organisms.
PRS72
availaBiliTy of dRugS Recommended By gloBal iniTiaTive foR 
chRonic oBSTRucTive lung diSeaSe (gold) foR ukRainian PaTienTS 
wiTh coPd
Iakovlieva L, Bondarenko D, Matyashova N, Tkachova O
National University of Pharmacy, Kharkiv, Ukraine
Objectives: A lifelong nature of COPD therapy requires significant costs from the 
patient’s budget. GOLD develops recommendations for the treatment of COPD, which 
correspond to the modern level of medicine and ensure proper quality of patients’ 
lives. The aim of this work is to identify the availability of drugs recommended by 
GOLD for patients in Ukraine from the perspective of physical availability of the 
drug in a pharmacy and in terms of its affordability. MethOds: To determine the 
affordability of drugs, the paying capacity adequacy rate (Ca.s.) for 2014 was calcu-
lated. Results: In the Ukrainian market, there are 18 out of 32 drugs recommended 
by GOLD for the treatment of stable COPD course. A group of long-acting anticholin-
ergics (2 out of 4 drugs) and combined drugs glucocorticosteroids + β 2-agonists in 
one inhaler (2 out of 4 drugs) is presented insufficiently, and long-acting combina-
tions of anticholinergic + β 2-agonists are not available in the market. According to 
capacity adequacy rate (Ca.s.), in 2014 a month of treatment with the studied drugs 
